MediShield Life Scheme (Amendment) Regulations 2022

No. S 711

MediShield Life Scheme Act 2015

MediShield Life Scheme
(Amendment) Regulations 2022

In exercise of the powers conferred by section 34 of the MediShield Life Scheme Act 2015, the Minister for Health makes the following Regulations:

Citation and commencement

1. These Regulations are the MediShield Life Scheme (Amendment) Regulations 2022 and come into operation on 1 September 2022.

Amendment of regulation 2

2. In regulation 2(1) of the MediShield Life Scheme Regulations 2015 (G.N. No. S 622/2015) (called in these Regulations the principal Regulations) —

(a)

after the definition of “admission date”, insert —

“ “approved cancer drug” means any active ingredient (or combination of active ingredients) in the dosage form and strength listed in the CDL and administered for the corresponding clinical indication listed in the CDL;”;

(b)

in the definition of “approved outpatient treatment”, replace paragraph (b) with —

“(b)	cancer drug treatment;”;

(c)

after the definition of “approved restructured hospital”, insert —

“ “cancer drug” means any drug, including any approved cancer drug, used for the treatment of neoplasms;

“cancer drug treatment” means —

(a)	the administration of any cancer drug for the treatment of neoplasms; or
(b)	any other medical treatment or services ancillary to the administration of any cancer drug for the treatment of neoplasms;

“CDL” means the Cancer Drug List published on the website of the Ministry of Health at https://www.moh.gov.sg;”;

(d)

in the definition of “medical treatment”, in paragraph (a), replace “treatment of neoplasms by chemotherapy” with “cancer drug treatment”; and

(e)

replace the definition of “treatment of neoplasms by chemotherapy” with —

“ “treatment of neoplasms” means the treatment of malignant neoplasms, certain benign neoplasms and neoplasms of uncertain behaviour.”.

Amendment of Third Schedule

3. In the Third Schedule to the principal Regulations, after paragraph 20, insert —

“21. The cost of any cancer drug administered to an outpatient that is not an approved cancer drug.”.

Amendment of Fourth Schedule

4. In the Fourth Schedule to the principal Regulations, in Part 2, under the heading “Subsidy status”, replace “Treatment of neoplasms by chemotherapy” with “Cancer drug treatment”.

Amendment of Sixth Schedule

5. In the Sixth Schedule to the principal Regulations, replace item 7 with —

“7.	Approved cancer drugs administered for treatment of neoplasms, received as outpatient medical treatment, where the approved cancer drugs administered in a month are listed in the CDL under —

(a)	only one of the following categories:

(i)	Category 1

$200 per month

(ii)	Category 2

$400 per month

(iii)

Category 3

$600 per month

(iv)	Category 4

$800 per month

(v)	Category 5

$1,000 per month

(vi)	Category 6

$1,200 per month

(vii)

Category 7

$1,400 per month

(viii)

Category 8

$1,600 per month

(ix)	Category 9

$1,800 per month

(x)	Category 10

$2,000 per month

(xi)	Category 12

$2,400 per month

(xii)

Category 15

$3,000 per month

(xiii)

Category 16

$3,200 per month

(xiv)

Category 19

$3,800 per month

(xv)	Category 26

$5,200 per month

(xvi)

Category 27

$5,400 per month

(xvii)

Category 46

$9,200 per month

(xviii)

Category 48

$9,600 per month

(b)	more than one of the categories listed in paragraph (a)

The highest amount per month specified in respect of any category of the approved cancer drugs administered in that month

7A.	Cancer drug treatment (excluding the cost of any cancer drug administered) received as outpatient medical treatment

$1,200 per year”.

[G.N. Nos. S 300/2018; S 465/2018; S 731/2018; S 190/2019; S 286/2019; S 866/2019; S 192/2020; S 224/2020; S 898/2020; S 933/2020; S 135/2021]

Made on 25 August 2022.

CHAN YENG KIT

Permanent Secretary,
Ministry of Health,
Singapore.

[MH 96:27/12; AG/LEGIS/SL/176A/2020/1 Vol. 1]

(To be presented to Parliament under section 34(4) of the MediShield Life Scheme Act 2015).

Search within Legislation